Ochronosis (Alkaptonuria Arthropathy)

Alkaptonuria (AKU) is a rare autosomal recessive inborn error of tyrosine metabolism. The downstream connective-tissue disease it causes is ochronosis, and the resulting joint disease is ochronotic arthropathy. The condition is defined by a triad that an examiner expects you to recite: dark urine, ochronotic pigmentation of connective tissue, and a progressive arthropathy.

The key conceptual point is the time course. Because the enzyme block is present from birth, the urine darkens on standing from infancy. However, the pigment that damages tissue takes decades to accumulate, so ochronosis and arthropathy are usually silent until the fourth decade of life. Patients therefore often present to orthopaedics with "early, severe, spine-dominant osteoarthritis" long before the metabolic diagnosis is made.

View larger

The whole topic uses "ochronosis" as a synonym for alkaptonuria, but the word actually describes the blue-black tissue pigmentation itself, which has two quite different causes. An examiner who asks "is all ochronosis alkaptonuria?" wants this distinction.

Endogenous (metabolic) ochronosis is the alkaptonuria described throughout this topic: a systemic, autosomal recessive HGD deficiency in which homogentisic acid polymerises and deposits in cartilage, discs, sclera, valves and tendons, producing the systemic ochronotic arthropathy.

Exogenous (acquired) ochronosis is a localised, skin-limited pigmentation with normal HGA and no arthropathy, caused by chronic external exposure to certain chemicals - most importantly long-term topical hydroquinone (skin-lightening / bleaching creams), and historically phenol, resorcinol, picric acid and some antimalarials. The chemical inhibits local homogentisic acid oxidase in the dermis, so HGA polymerises and deposits as identical-looking pigment, but only in the treated skin.

For the orthopaedic surgeon the practical point is the reverse: the systemic, arthropathy-causing ochronosis you meet at the operating table is essentially always the endogenous, alkaptonuric form - but knowing that a skin-limited, HGA-negative exogenous variant exists is the higher-mark answer.

There is no single named "classification" of ochronosis, but examiners expect you to organise the disease by system involvement and by the typical sequence in which sites are affected.

Age and Mode of Presentation

• Infancy/childhood: dark-staining urine (nappies, underwear) - often the only sign and frequently missed.
• Fourth decade onward: insidious low back pain and stiffness; progressive large-joint pain.
• Spot signs: scleral and ear pigment, blue-grey skin over sweat-gland-rich areas, dark cerumen.

Musculoskeletal Features

• Axial: chronic low back pain, reduced spinal mobility, loss of lumbar lordosis, progressive stiffening toward ankylosis.
• Peripheral: large-joint osteoarthritis (knee most common), effusions, mechanical symptoms from cartilage fragments.
• Tendon: spontaneous rupture (classically the Achilles) due to embrittlement.

Extra-articular Features

• Cardiac: aortic valve pigmentation, stenosis and aortic root involvement; coronary and valvular calcification.
• Genitourinary: renal and prostatic calculi.
• Ophthalmic/cutaneous: scleral pigment, pigmented pinna, skin discolouration.

The topic differentiates ochronosis from ankylosing spondylitis, but each of its three cardinal signs - calcified discs, dark urine and blue-grey pigment - has its own differential that the examiner can probe. Working through them is what separates a safe candidate from a memorised one.

Management has two arms: disease-modifying metabolic therapy to reduce HGA, and supportive/orthopaedic care for established connective-tissue damage that pigment has already caused.

The Surgeon's Perspective

Ochronosis is the rare metabolic disease that an orthopaedic surgeon is genuinely likely to encounter at the operating table. The first clue is often black cartilage discovered unexpectedly during arthroplasty in a patient labelled as having "primary" osteoarthritis. Recognising this prompts the metabolic diagnosis, family screening and systemic assessment (especially the aortic valve).

Why the Spine Comes First

The intervertebral disc is rich in type II collagen and proteoglycan and has a high collagen turnover environment that favours pigment binding. The result is the characteristic multilevel disc calcification that distinguishes ochronotic spondylopathy from other causes of a stiff spine and predates peripheral disease.

A Model Disease for Metabolic Therapy

AKU is also a teaching example of rational drug design: because the defect is loss of a downstream enzyme, blocking the upstream enzyme (HPPD) with nitisinone reduces the toxic intermediate. The trade-off - accumulation of tyrosine - illustrates the principle that re-routing a metabolic pathway shifts, rather than abolishes, the metabolic burden.

Ochronosis is a rare disease, so practice is shaped by specialist centres and rare-disease frameworks rather than mainstream arthroplasty guidelines. The biology is universal; access to diagnosis and to nitisinone is not.

Global Epidemiology

• Alkaptonuria is rare worldwide, with an estimated birth prevalence of roughly 1 in 250,000 to 1 in 1,000,000 in most populations.
• Geographic clusters of much higher prevalence exist, notably in Slovakia and parts of the Dominican Republic, reflecting founder effects in the HGD gene.
• Many distinct pathogenic HGD variants have been catalogued internationally (for example, large variant cohorts described in Russia), underpinning genetic confirmation and family screening.

Therapy Access and Regulatory Status

There is broad consensus that HGA-lowering with nitisinone plus structured monitoring is the rational disease-modifying approach, and that end-stage arthropathy is treated with arthroplasty using conventional principles adapted for stiff joints and friable tissue.

Registries & Surveillance

• No large arthroplasty registry isolates ochronotic arthropathy, but national joint registries (NJR, AJRR, AOANJRR, SHAR, NZJR) capture implant survival data that inform implant choice when these patients require replacement.
• Rare-disease registries and dedicated AKU cohorts (linked to the SONIA programme and patient organisations such as the AKU Society) are the principal source of natural-history and treatment-outcome data.

High- vs Limited-Resource Practice Variation

• High-resource settings: access to genetic confirmation, nitisinone with tyrosine/ophthalmic monitoring, dietetics and elective multi-joint arthroplasty.
• Limited-resource settings: diagnosis is often delayed to the arthroplasty table; management relies on analgesia, physiotherapy and replacement when feasible, with limited access to nitisinone.

1. Ranganath LR, Psarelli EE, Arnoux JB, et al. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2020. PMID 32822600.

2. Ranganath LR, Milan AM, Hughes AT, et al. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): a randomised, open-label, dose-response study. Ann Rheum Dis. 2014. PMID 25475116.

3. Rajkumar N, Soundarrajan D, Dhanasekararaja P, Rajasekaran S. Clinical and radiological outcomes of total joint arthroplasty in patients with ochronotic arthropathy. Eur J Orthop Surg Traumatol. 2020. PMID 32172376.

4. Khedr M, Cooper MS, Hughes AT, et al. Nitisinone causes acquired tyrosinosis in alkaptonuria. J Inherit Metab Dis. 2020. PMID 32083330.

5. Mistry JB, Bukhari M, Taylor AM. Alkaptonuria. Rare Dis. 2013. PMID 25003018.

6. Grosicka A, Kucharz EJ. Alkaptonuria. Wiad Lek. 2009. PMID 20229718.

7. Soltysova A, Kuzin A, Samarkina E, Zatkova A. Alkaptonuria in Russia. Eur J Hum Genet. 2021. PMID 34504318.